RxDoctor Payments Data

Lilia Escobar

Physician Assistant · Rio Grande City, TXNPI 1134545387

Payments from drug & device makers

$6,016in general payments, 2019–2025

Across 356 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$617
  • Novo Nordisk$586
  • Merck$576
  • Sumitomo Pharma America, Inc.$332
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$5,97799%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,016 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide389$419,784
OzempicSemaglutide411$409,361
Breztri AerosphereBudesonide/Glycopyr/Formoterol259$224,528
LinzessLinaclotide158$144,255
JardianceEmpagliflozin89$102,482
FarxigaDapagliflozin Propanediol65$78,654
JanuviaSitagliptin Phosphate72$75,286
ProliaDenosumab42$70,430
RybelsusSemaglutide44$64,014
MyrbetriqMirabegron62$63,007
TrulicityDulaglutide43$51,650
EntrestoSacubitril/Valsartan40$42,399
EliquisApixaban39$39,137
XareltoRivaroxaban28$39,016
TradjentaLinagliptin39$35,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$586$473,375455 claims
Lilly USA, LLCMounjaro, Trulicity$617$471,434432 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,116$303,182324 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Glyxambi, Synjardy Xr$120$224,081192 claims
AbbVieLinzess, Vraylar, Namzaric$1,465$199,086199 claims
MerckJanuvia, Janumet Xr$576$103,66899 claims
AmgenProlia$249$70,43042 claims
Astellas Pharma US IncMyrbetriq$108$63,00762 claims
NovartisEntresto$60$42,39940 claims
PfizerEliquis$72$39,13739 claims
Johnson & JohnsonXarelto$146$39,01628 claims
Sumitomo Pharma America, Inc.Gemtesa$332$14,81219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Rio Grande City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →